Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Farde

Showing results (21-30 of 207) with videos related to

Pageof 21
Sort By:
Ernst Schering Research Foundation Workshop|July 14, 2004
PET for drug developmentC Halldin, B Gulyás, L Farde
Nuclear Medicine and Biology|May 1, 1994
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomographyC Halldin, T Högberg, L Farde
Current Pharmaceutical Design|January 5, 2002
PET studies with carbon-11 radioligands in neuropsychopharmacological drug developmentC Halldin, B Gulyás, L Farde
Acta Radiologica. Supplementum|January 1, 1991
Kinetic analysis of receptor binding with positron emission tomographyL Eriksson, L Farde, G Rosenquist
Nature|February 13, 1997
D2 dopamine receptors and personality traitsL Farde, J P Gustavsson, E Jönsson
Acta Psychiatrica Scandinavica. Supplementum|January 1, 1989
Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PETF A Wiesel, L Farde, C Halldin
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1997
Imaging the living human brain: magnetic resonance imaging and positron emission tomographyN D Volkow, B Rosen, L Farde
Synapse (New York, N.Y.)|October 6, 2000
Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET studyY H Chou, C Halldin, L Farde
Psychopharmacology|January 1, 1992
Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidolA L Nordström, L Farde, C Halldin
Life Sciences|August 17, 1987
Quantitative determination of D2 dopamine receptor characteristics in healthy human subjects and psychiatric patientsG Sedvall, L Farde, F A Wiesel
Pageof 21

Showing results (21-30 of 207) with videos related to

Sort By:
Pageof 21
Ernst Schering Research Foundation Workshop|July 14, 2004
PET for drug developmentC Halldin, B Gulyás, L Farde
Nuclear Medicine and Biology|May 1, 1994
Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomographyC Halldin, T Högberg, L Farde
Current Pharmaceutical Design|January 5, 2002
PET studies with carbon-11 radioligands in neuropsychopharmacological drug developmentC Halldin, B Gulyás, L Farde
Acta Radiologica. Supplementum|January 1, 1991
Kinetic analysis of receptor binding with positron emission tomographyL Eriksson, L Farde, G Rosenquist
Nature|February 13, 1997
D2 dopamine receptors and personality traitsL Farde, J P Gustavsson, E Jönsson
Acta Psychiatrica Scandinavica. Supplementum|January 1, 1989
Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PETF A Wiesel, L Farde, C Halldin
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1997
Imaging the living human brain: magnetic resonance imaging and positron emission tomographyN D Volkow, B Rosen, L Farde
Synapse (New York, N.Y.)|October 6, 2000
Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET studyY H Chou, C Halldin, L Farde
Psychopharmacology|January 1, 1992
Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidolA L Nordström, L Farde, C Halldin
Life Sciences|August 17, 1987
Quantitative determination of D2 dopamine receptor characteristics in healthy human subjects and psychiatric patientsG Sedvall, L Farde, F A Wiesel
Pageof 21